| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Stephen Mayo is Director at ALLO, with reported holdings spanning 2 companies. Stephen Mayo's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $374K at current prices.
Our model assigns Stephen Mayo a middling insider score of 63/100, based on 4 past trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +25.6%.
Stephen Mayo's largest disclosed position is in SRPT as Director, worth about $346K. The SRPT filings lean toward selling, a net 11,232 shares.
Stephen Mayo has 22 Form 4 filings on record from March 2021 to June 2026, across 3 companies: Director at Allogene Therapeutics (ALLO), 2022–2026; Director at Sarepta Therapeutics (SRPT), 2021–2026; Director at Merck & (MRK), 2021–2026.
The 28 reported transactions were 17 option or other derivative awards, 7 stock awards and 4 open-market sales.
Counted by filing, the open-market trades come to no purchases and 4 sales worth about $646K.
The largest open-market sale was 3,135 shares of SRPT at an average $122.96 on March 5, 2024, about $385K. Twelve months later SRPT was down 12%.
None of the 3 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | SRPT Sarepta Therapeutics, Inc. | Director | Sell | 7,239 | $17.02 | $123,207.78 | -80.4% | -11.3% | - | |
| Mar 5, 2024 | SRPT Sarepta Therapeutics, Inc. | Director | Sell | 3,135 | $122.96 | $385,479.60 | -32.1% | +1.1% | -12.4% | |
| Aug 7, 2023 | ALLO Allogene Therapeutics, Inc. | Director | Sell | 10,000 | $4.29 | $42,855.00 | -28.3% | -25.6% | -40.0% | |
| Nov 17, 2022 | SRPT Sarepta Therapeutics, Inc. | Director | Sell | 858 | $109.92 | $94,311.36 | -11.8% | +13.4% | -24.4% |